Coherus Oncology
Market cap $74.0M 154.5M shares (10-Q, Oct 31, 2026) × $0.479 close Nov 17, 2026
Most recent annual filing: 2026-03-09
- Tagmokitug + pasritamig Ph1 startFall 2026Tagmokitug + pasritamig Ph1 start, Fall 2026, routine
- Casdozokitug Ph2 topline1H 2027Casdozokitug Ph2 topline, 1H 2027, thesis-defining
- company financing1Q 2027company financing, 1Q 2027, routine
- UDENYCA corporate updateMar 31, 2027UDENYCA corporate update, Mar 31, 2027, routine
- Term B Loan corporate updateSep 1 – Apr 30, 2028Term B Loan corporate update, Sep 1 – Apr 30, 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
casdozokitug
CHS-388tagmokitug
tagmokitug
CHS-114Technology platforms
TREGCHECK
Clinical development program platform evaluating tagmokitug (anti-CCR8 cytolytic antibody) across multiple solid tumor settings, including ESCC, HNSCC, gastric/GEJ/esophageal, and colorectal cancers; focused on CCR8-positive regulatory T cell depletion to overcome immune resistance
Targets: CCR8
Discontinued (1)
- tagmokitug — Head and Neck Squamous Cell Carcinoma · strategic deprioritization to focus resources on esophageal cancer lead indication
Capital (as filed)
- Cash
- $53.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $30.1M Sep 30, 2026
- Operating cash flow
- −$34.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $83.6M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-08-28 424B5 · At-the-market program up to $50.0M
- 2026-08-28 424B3 · At-the-market program up to $92.5M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (6)
- 2026-11-10 UPDATE: Coherus Oncology (CHRS) - The Coin Flip Outran the Cash 🔒 Paid
- 2026-10-29 UPDATE: Coherus Oncology (CHRS) - Tagmokitug Finally Shows Its Cards 🔒 Paid
- 2026-08-28 UPDATE: Coherus Oncology (CHRS) - They Reloaded the ATM 🔒 Paid
- 2026-08-17 UPDATE: Coherus Oncology (CHRS) - They Funded the Coin Flip 🔒 Paid
- 2026-08-06 UPDATE: Coherus Oncology (CHRS) - The Coin Flip Moved to October 🔒 Paid
- 2026-05-20 Coherus Oncology (CHRS) — Scientific Deep Dive for LOQTORZI, Casdozokitug, and Tagmokitug
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (6 calls)
Every verdict Biotech Distilled has published on Coherus Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-20 Watch Coherus Oncology (CHRS) — Scientific Deep Dive for LOQTORZI, Casdozokitug, and Tagmokitug The mid-2026 casdozokitug Phase 2 randomized readout is a binary coin flip; the author recommends waiting for data rather than committing capital ahead of an unknowable 72-patient outcome.
- 2026-08-06 Speculative buy speculative UPDATE: Coherus Oncology (CHRS) - The Coin Flip Moved to October Enrollment is complete on the casdozo HCC Phase 2, the catalyst now has a named month (early October), and opex is genuinely shrinking — sufficient to justify a first tranche for binary-event investors, sized to survive a 60% drawdown.
- 2026-08-17 Hold UPDATE: Coherus Oncology (CHRS) - They Funded the Coin Flip The $55M Innovatus debt facility removes the pre-readout dilutive equity raise risk, but the capital structure is now heavier with a senior IP lien and a liquidity covenant, shifting the risk/reward geometry enough to step back from Speculative Buy to Hold for those not yet positioned.
- 2026-08-28 Hold UPDATE: Coherus Oncology (CHRS) - They Reloaded the ATM The new $50M Leerink ATM adds a dilution vector at management's discretion but does not change the underlying binary setup; the catalyst is intact roughly five weeks out and the verdict remains Hold.
- 2026-10-29 Hold UPDATE: Coherus Oncology (CHRS) - Tagmokitug Finally Shows Its Cards Tagmokitug's 6/8 response rate in 1L ESCC provides genuine proof-of-concept with denominators, but the sample is tiny, the 2L HNSCC cohort missed the bar, and the casdozokitug binary remains the dominant value driver — no change warranted for existing holders.
- 2026-11-10 Avoid UPDATE: Coherus Oncology (CHRS) - The Coin Flip Outran the Cash The casdozokitug binary slipped to 1H 2027, a going-concern warning appeared, the Innovatus covenant floor may have risen above available free cash, and a dilutive equity raise ahead of the readout is now the base case — whoever buys equity today is likely to be diluted before the coin is flipped.
- Long call · opened Aug 6, 2026 at $1.26 · closed Nov 10, 2026 (flipped bearish (avoid)) at $0.641 · -49.3% vs XBI +0.4%
- Avoid call · opened Nov 10, 2026 at $0.641 · -25.3% vs XBI -6.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027. THIRD QUARTER 2026 FINANCIAL RESULTS Net revenue from continuing operations was $14.3 million and $11.6 million during the three months ended September 30, 2026 and 2025, respectively, and $40.9 million and $29.4 million during the nine months ended September 30, 2026 and 2025, respectively.”
matched to Casdozokitug · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (29)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseCoherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateCoherus just restructured the company around esophageal cancer, cut headcount 30%, pushed the casdozo HCC readout to 1H 2027, and filed a going-concern 10-Q with $83.6M in cash — the thesis just changed shape, not just timing.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 29, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Oct 28, 2026ReleaseCoherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development→ BD updateBD extracted 1 program update from this document → CHRS pipeline
- Oct 26, 2026ReleaseCoherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
- Oct 14, 2026ReleaseCoherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
- Sep 23, 2026ReleaseCoherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
- Aug 31, 2026ReleaseCoherus to Participate in Upcoming Investor Conferences
- Aug 28, 20268-KCurrent report: other events→ BD updateSix weeks before the casdozokitug coin flip, Coherus swapped its exhausted TD Cowen ATM for a fresh $50M Leerink Partners facility — reopening the dilution tap into a 22.6% post-Innovatus rally and changing the pre-readout capital structure calculus I laid out on August 17.
- Aug 28, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Aug 28, 2026424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
- Aug 17, 2026ReleaseCoherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
- Aug 17, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Aug 17, 20268-KCurrent report: material agreement, agreement terminated, debt / obligation
- Aug 5, 2026ReleasePrint Page
- Aug 5, 2026ReleaseCoherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1
- Aug 5, 202610-QQuarterly report
- Jun 15, 20268-KCurrent report: auditor change
- Jun 1, 20268-KCurrent report: shareholder vote
- May 28, 2026DEFA14AProxy soliciting material
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 202610-QQuarterly report
- May 5, 2026DEFA14AProxy soliciting material
- Apr 20, 2026DEF 14AProxy statement
- Apr 14, 2026DEFA14AProxy soliciting material
- Mar 9, 20268-KCurrent report: results of operations · EX-99.1
- Mar 9, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 5, 2026S-8Employee plan registration
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 11, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026SCHEDULE 13G/A13G amendment
- Apr 27, 2026SCHEDULE 13G/A13G amendment
- Apr 20, 2026ARSAnnual report to shareholders
- Apr 9, 2026PRE 14APRE 14A
- Mar 26, 2026SCHEDULE 13G/A13G amendment